Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,otherLiab,goodWill,treasuryStock,otherAssets,cash,totalCurrentLiabilities,deferredLongTermAssetCharges,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,longTermInvestments,shortTermInvestments,netReceivables,longTermDebt,inventory,accountsPayable,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,changeInCash,repurchaseOfStock,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,otherCashflowsFromInvestingActivities,dividendsPaid,changeToInventory,changeToAccountReceivables,otherCashflowsFromFinancingActivities,changeToNetincome,capitalExpenditures,WC,language,region,quoteType,triggerable,quoteSourceName,currency,market,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,shortName,exchange,marketState,twoHundredDayAverageChangePercent,exchangeDataDelayedBy,esgPopulated,tradeable,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,dividendDate,trailingAnnualDividendRate,trailingPE,trailingAnnualDividendYield,epsTrailingTwelveMonths,priceHint,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,marketCap,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,Shares Short 4,Short Ratio 4,Short % of Float 4,Short % of Shares Outstanding 4,Shares Short (prior month ) 4,Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,industry
t0,GNHAY,1115300000.0,324276000,,,,447800000,0,,0,0,,,,,,,0,0,0,0,0,,,,1487700000.0,1194100000.0,3569800000.0,118700000.0,5211700000.0,700000.0,4000000.0,3863000000.0,54500000.0,966800000.0,-293900000.0,105400000.0,730000000.0,544000000.0,65700000.0,-274900000.0,302300000.0,1609000000.0,740500000.0,4400000.0,492400000.0,539800000.0,339800000.0,162100000.0,0.0,,,,,,,,,,,,,,,,,1065000000.0,en-US,US,EQUITY,False,Delayed Quote,USD,us_market,30.02,1629908245,0.0,30.02,30.02,30.02,58,VIFOR PHARMA AG,PNK,PREPRE,0.06712537,0,False,False,0.0,30.02 - 30.02,30.02,finmb_875519,Other OTC,Vifor Pharma AG,CHF,82,157,4.210001,0.16311511,25.81 - 32.1,-2.079998,-0.064797446,25.81,32.1,1622073600,2.0,24.950134,0.06662225,1.2032,2,11.0086,27.536572,2.483429,0.09018657,28.131653,1.8883476,9734765568,2.726959,15,America/New_York,EDT,-14400000,1.3,,,32.1,25.81,27.54,28.13,82,157,324.28M,,233.02M,,,,,,,,0.44,1.65%,2.00,6.66%,,60.71%,"May 26, 2021","May 09, 2021",,,"Dec 30, 2020","Dec 30, 2020",20.41%,17.78%,3.86%,6.13%,1.76B,5.43,,1.06B,513.3M,138.7M,1.20,,734.4M,2.27,609.7M,15.18,2.96,11.01,423.8M,79.34M,Value,9014,Healthcare,2600,2,7,"Vifor Pharma AG, a pharmaceutical company, focuses on the development, manufacture, and commercialization of pharmaceutical products in Switzerland, rest of Europe, the United States, and internationally. The company offers Ferinject/Injectafer, a solution of ferric carboxymaltose used for the treatment of iron deficiency and iron deficiency anemia; Maltofer, an oral iron polymaltose complex for infants, children, adolescents, and pregnant woman with iron deficiency; and Mircera, a long-acting erythropoiesis-stimulating agent (ESA) to treat symptomatic anemia associated with the chronic kidney disease (CKD). It also provides Retacrit, a short-acting ESA; Venofer, an intravenous iron sucrose used in the intravenous treatment of iron deficiency; and Velphoro, a non-calcium, iron-based chewable phosphate binder for the treatment of hyperphosphatemia in adults with CKD undergoing dialysis. In addition, the company offers Rayaldee, an orally administered, extended release formulation of calcifediol for the treatment of secondary hyperparathyroidism in patients with CKD; Veltassa for the treatment of hyperkalaemia in CKD and chronic heart failure patients; and Invokana to treat diabetic kidney disease. Further, it developing Vadadustat, an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of anemia due to chronic kidney disease; Avacopan, an orally-administered, highly selective inhibitor of C5aR1 for the treatment of orphan and rare renal diseases; ANG-3777 for the treatment of delayed graft function and cardiac surgery-associated acute kidney injury; Difelikefalin for the treatment for chronic kidney disease-associated pruritus; and VIT-2763 to treat beta-thalassemia. Vifor Pharma AG has a strategic partnership with Fresenius Kabi. The company was formerly known as Galenica AG and changed its name to Vifor Pharma AG in April 2017. Vifor Pharma AG was founded in 1872 and is headquartered in Sankt Gallen, Switzerland.",Sankt Gallen,41 58 851 80 00,1,1609372800,1625097600,1,Switzerland,http://www.viforpharma.com,86400,1,Rechenstrasse 37,Drug Manufacturers—Specialty & Generic
t-1,GNHAY,1115300000.0,324276000,,,,447800000,0,,0,0,,,,,,,0,0,0,0,0,,,,1487700000.0,1194100000.0,3569800000.0,118700000.0,5211700000.0,700000.0,4000000.0,3863000000.0,54500000.0,966800000.0,-293900000.0,105400000.0,730000000.0,544000000.0,65700000.0,-274900000.0,302300000.0,1609000000.0,740500000.0,4400000.0,492400000.0,539800000.0,339800000.0,162100000.0,0.0,,,,,,,,,,,,,,,,,1065000000.0,en-US,US,EQUITY,False,Delayed Quote,USD,us_market,30.02,1629908245,0.0,30.02,30.02,30.02,58,VIFOR PHARMA AG,PNK,PREPRE,0.06712537,0,False,False,0.0,30.02 - 30.02,30.02,finmb_875519,Other OTC,Vifor Pharma AG,CHF,82,157,4.210001,0.16311511,25.81 - 32.1,-2.079998,-0.064797446,25.81,32.1,1622073600,2.0,24.950134,0.06662225,1.2032,2,11.0086,27.536572,2.483429,0.09018657,28.131653,1.8883476,9734765568,2.726959,15,America/New_York,EDT,-14400000,1.3,,,32.1,25.81,27.54,28.13,82,157,324.28M,,233.02M,,,,,,,,0.44,1.65%,2.00,6.66%,,60.71%,"May 26, 2021","May 09, 2021",,,"Dec 30, 2020","Dec 30, 2020",20.41%,17.78%,3.86%,6.13%,1.76B,5.43,,1.06B,513.3M,138.7M,1.20,,734.4M,2.27,609.7M,15.18,2.96,11.01,423.8M,79.34M,Value,9014,Healthcare,2600,2,7,"Vifor Pharma AG, a pharmaceutical company, focuses on the development, manufacture, and commercialization of pharmaceutical products in Switzerland, rest of Europe, the United States, and internationally. The company offers Ferinject/Injectafer, a solution of ferric carboxymaltose used for the treatment of iron deficiency and iron deficiency anemia; Maltofer, an oral iron polymaltose complex for infants, children, adolescents, and pregnant woman with iron deficiency; and Mircera, a long-acting erythropoiesis-stimulating agent (ESA) to treat symptomatic anemia associated with the chronic kidney disease (CKD). It also provides Retacrit, a short-acting ESA; Venofer, an intravenous iron sucrose used in the intravenous treatment of iron deficiency; and Velphoro, a non-calcium, iron-based chewable phosphate binder for the treatment of hyperphosphatemia in adults with CKD undergoing dialysis. In addition, the company offers Rayaldee, an orally administered, extended release formulation of calcifediol for the treatment of secondary hyperparathyroidism in patients with CKD; Veltassa for the treatment of hyperkalaemia in CKD and chronic heart failure patients; and Invokana to treat diabetic kidney disease. Further, it developing Vadadustat, an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of anemia due to chronic kidney disease; Avacopan, an orally-administered, highly selective inhibitor of C5aR1 for the treatment of orphan and rare renal diseases; ANG-3777 for the treatment of delayed graft function and cardiac surgery-associated acute kidney injury; Difelikefalin for the treatment for chronic kidney disease-associated pruritus; and VIT-2763 to treat beta-thalassemia. Vifor Pharma AG has a strategic partnership with Fresenius Kabi. The company was formerly known as Galenica AG and changed its name to Vifor Pharma AG in April 2017. Vifor Pharma AG was founded in 1872 and is headquartered in Sankt Gallen, Switzerland.",Sankt Gallen,41 58 851 80 00,1,1609372800,1625097600,1,Switzerland,http://www.viforpharma.com,86400,1,Rechenstrasse 37,Drug Manufacturers—Specialty & Generic
t-2,GNHAY,736100000.0,324276000,78100000.0,,59000000.0,379500000,33950000,149150000.0,294800000,67550000,67550000.0,,-9650000.0,,,,5650000,482750000,415200000,187950000,-8550000,,53350000.0,33950000.0,2557100000.0,1226800000.0,3293200000.0,86100000.0,4899500000.0,700000.0,2700000.0,3527200000.0,57300000.0,,-234700000.0,69100000.0,304700000.0,548600000.0,53200000.0,-213500000.0,351400000.0,1261700000.0,660200000.0,,485700000.0,565500000.0,420200000.0,140000000.0,2000000.0,-76400000.0,-4700000.0,-127000000.0,-11050000.0,-120100000.0,-12500000.0,-2950000.0,86300000.0,85050000.0,-50000.0,-64800000.0,-36500000.0,-10400000.0,-45000000.0,23250000.0,-13600000.0,713100000.0,en-US,US,EQUITY,False,Delayed Quote,USD,us_market,30.02,1629908245,0.0,30.02,30.02,30.02,58,VIFOR PHARMA AG,PNK,PREPRE,0.06712537,0,False,False,0.0,30.02 - 30.02,30.02,finmb_875519,Other OTC,Vifor Pharma AG,CHF,82,157,4.210001,0.16311511,25.81 - 32.1,-2.079998,-0.064797446,25.81,32.1,1622073600,2.0,24.950134,0.06662225,1.2032,2,11.0086,27.536572,2.483429,0.09018657,28.131653,1.8883476,9734765568,2.726959,15,America/New_York,EDT,-14400000,1.3,,,32.1,25.81,27.54,28.13,82,157,324.28M,,233.02M,,,,,,,,0.44,1.65%,2.00,6.66%,,60.71%,"May 26, 2021","May 09, 2021",,,"Dec 30, 2020","Dec 30, 2020",20.41%,17.78%,3.86%,6.13%,1.76B,5.43,,1.06B,513.3M,138.7M,1.20,,734.4M,2.27,609.7M,15.18,2.96,11.01,423.8M,79.34M,Value,9014,Healthcare,2600,2,7,"Vifor Pharma AG, a pharmaceutical company, focuses on the development, manufacture, and commercialization of pharmaceutical products in Switzerland, rest of Europe, the United States, and internationally. The company offers Ferinject/Injectafer, a solution of ferric carboxymaltose used for the treatment of iron deficiency and iron deficiency anemia; Maltofer, an oral iron polymaltose complex for infants, children, adolescents, and pregnant woman with iron deficiency; and Mircera, a long-acting erythropoiesis-stimulating agent (ESA) to treat symptomatic anemia associated with the chronic kidney disease (CKD). It also provides Retacrit, a short-acting ESA; Venofer, an intravenous iron sucrose used in the intravenous treatment of iron deficiency; and Velphoro, a non-calcium, iron-based chewable phosphate binder for the treatment of hyperphosphatemia in adults with CKD undergoing dialysis. In addition, the company offers Rayaldee, an orally administered, extended release formulation of calcifediol for the treatment of secondary hyperparathyroidism in patients with CKD; Veltassa for the treatment of hyperkalaemia in CKD and chronic heart failure patients; and Invokana to treat diabetic kidney disease. Further, it developing Vadadustat, an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of anemia due to chronic kidney disease; Avacopan, an orally-administered, highly selective inhibitor of C5aR1 for the treatment of orphan and rare renal diseases; ANG-3777 for the treatment of delayed graft function and cardiac surgery-associated acute kidney injury; Difelikefalin for the treatment for chronic kidney disease-associated pruritus; and VIT-2763 to treat beta-thalassemia. Vifor Pharma AG has a strategic partnership with Fresenius Kabi. The company was formerly known as Galenica AG and changed its name to Vifor Pharma AG in April 2017. Vifor Pharma AG was founded in 1872 and is headquartered in Sankt Gallen, Switzerland.",Sankt Gallen,41 58 851 80 00,1,1609372800,1625097600,1,Switzerland,http://www.viforpharma.com,86400,1,Rechenstrasse 37,Drug Manufacturers—Specialty & Generic
t-3,GNHAY,736100000.0,324276000,78100000.0,,59000000.0,379500000,33950000,149150000.0,294800000,67550000,67550000.0,,-9650000.0,,,,5650000,482750000,415200000,187950000,-8550000,,53350000.0,33950000.0,2557100000.0,1226800000.0,3293200000.0,86100000.0,4899500000.0,700000.0,2700000.0,3527200000.0,57300000.0,,-234700000.0,69100000.0,304700000.0,548600000.0,53200000.0,-213500000.0,351400000.0,1261700000.0,660200000.0,,485700000.0,565500000.0,420200000.0,140000000.0,2000000.0,-76400000.0,-4700000.0,-127000000.0,-11050000.0,-120100000.0,-12500000.0,-2950000.0,86300000.0,85050000.0,-50000.0,-64800000.0,-36500000.0,-10400000.0,-45000000.0,23250000.0,-13600000.0,713100000.0,en-US,US,EQUITY,False,Delayed Quote,USD,us_market,30.02,1629908245,0.0,30.02,30.02,30.02,58,VIFOR PHARMA AG,PNK,PREPRE,0.06712537,0,False,False,0.0,30.02 - 30.02,30.02,finmb_875519,Other OTC,Vifor Pharma AG,CHF,82,157,4.210001,0.16311511,25.81 - 32.1,-2.079998,-0.064797446,25.81,32.1,1622073600,2.0,24.950134,0.06662225,1.2032,2,11.0086,27.536572,2.483429,0.09018657,28.131653,1.8883476,9734765568,2.726959,15,America/New_York,EDT,-14400000,1.3,,,32.1,25.81,27.54,28.13,82,157,324.28M,,233.02M,,,,,,,,0.44,1.65%,2.00,6.66%,,60.71%,"May 26, 2021","May 09, 2021",,,"Dec 30, 2020","Dec 30, 2020",20.41%,17.78%,3.86%,6.13%,1.76B,5.43,,1.06B,513.3M,138.7M,1.20,,734.4M,2.27,609.7M,15.18,2.96,11.01,423.8M,79.34M,Value,9014,Healthcare,2600,2,7,"Vifor Pharma AG, a pharmaceutical company, focuses on the development, manufacture, and commercialization of pharmaceutical products in Switzerland, rest of Europe, the United States, and internationally. The company offers Ferinject/Injectafer, a solution of ferric carboxymaltose used for the treatment of iron deficiency and iron deficiency anemia; Maltofer, an oral iron polymaltose complex for infants, children, adolescents, and pregnant woman with iron deficiency; and Mircera, a long-acting erythropoiesis-stimulating agent (ESA) to treat symptomatic anemia associated with the chronic kidney disease (CKD). It also provides Retacrit, a short-acting ESA; Venofer, an intravenous iron sucrose used in the intravenous treatment of iron deficiency; and Velphoro, a non-calcium, iron-based chewable phosphate binder for the treatment of hyperphosphatemia in adults with CKD undergoing dialysis. In addition, the company offers Rayaldee, an orally administered, extended release formulation of calcifediol for the treatment of secondary hyperparathyroidism in patients with CKD; Veltassa for the treatment of hyperkalaemia in CKD and chronic heart failure patients; and Invokana to treat diabetic kidney disease. Further, it developing Vadadustat, an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of anemia due to chronic kidney disease; Avacopan, an orally-administered, highly selective inhibitor of C5aR1 for the treatment of orphan and rare renal diseases; ANG-3777 for the treatment of delayed graft function and cardiac surgery-associated acute kidney injury; Difelikefalin for the treatment for chronic kidney disease-associated pruritus; and VIT-2763 to treat beta-thalassemia. Vifor Pharma AG has a strategic partnership with Fresenius Kabi. The company was formerly known as Galenica AG and changed its name to Vifor Pharma AG in April 2017. Vifor Pharma AG was founded in 1872 and is headquartered in Sankt Gallen, Switzerland.",Sankt Gallen,41 58 851 80 00,1,1609372800,1625097600,1,Switzerland,http://www.viforpharma.com,86400,1,Rechenstrasse 37,Drug Manufacturers—Specialty & Generic
